Engineered immune cells take on deadly brain tumors in new trial
NCT ID NCT03170141
First seen Apr 29, 2026 · Last updated May 23, 2026 · Updated 6 times
Summary
This early-stage trial tests a personalized treatment for glioblastoma, an aggressive brain cancer. It uses a patient's own immune cells, modified to better recognize and attack the tumor, combined with chemotherapy. The study aims to check safety and see if the treatment can shrink tumors or slow the disease. It is open to patients aged 6 to 70 with recurrent glioblastoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, 518000, China
Conditions
Explore the condition pages connected to this study.